Research programme: VHH antibodies - BigHat Biosciences/Amgen
Latest Information Update: 08 Jan 2024
At a glance
- Originator BigHat Biosciences
- Developer Amgen; BigHat Biosciences
- Class Single-domain antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified